Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy
Asia Pacific Allergy
; (4): 126-128, 2014.
Article
em En
| WPRIM
| ID: wpr-749980
Biblioteca responsável:
WPRO
ABSTRACT
Anaphylaxis is a fatal and systemic allergic reaction, which can be prevented by avoiding exposure to a causative agent. However, the causative agent cannot be identified in all cases and may be hardly avoided. A 41-year-old man, diagnosed with idiopathic anaphylaxis, experienced 6 anaphylactic events over 7 months, requiring 4 emergency department (ER) visits and 3 epinephrine self-injections. Anti-immunoglobulin E (IgE) therapy was introduced to prevent further anaphylactic events. He experienced no anaphylactic events during 13 months of 4 monthly injections from the beginning until his most recent ER visit because of a similar anaphylactic event. We report a patient who experienced recurrent anaphylactic events that were prevented effectively by anti-IgE therapy with omalizumab. Anti-IgE therapy might be considered as an option to prevent anaphylactic events in patients for whom the causative agent(s) cannot be identified or avoided.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Imunoglobulina E
/
Epinefrina
/
Serviço Hospitalar de Emergência
/
Omalizumab
/
Aconselhamento a Distância
/
Hipersensibilidade
/
Hipersensibilidade Imediata
/
Anafilaxia
Limite:
Adult
/
Humans
Idioma:
En
Revista:
Asia Pacific Allergy
Ano de publicação:
2014
Tipo de documento:
Article